Dorsey & Whitney Trust CO LLC Purchases 9,989 Shares of Pfizer Inc. (NYSE:PFE)

Dorsey & Whitney Trust CO LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,467 shares of the biopharmaceutical company’s stock after acquiring an additional 9,989 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Pfizer were worth $2,011,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC grew its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the 4th quarter valued at $36,000. DiNuzzo Private Wealth Inc. purchased a new stake in Pfizer in the 4th quarter worth $37,000. Finally, Life Planning Partners Inc bought a new position in shares of Pfizer during the 4th quarter valued at about $39,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on PFE shares. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, July 10th. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Barclays increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 10th. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $34.50.

Pfizer Trading Up 0.9 %

Shares of NYSE PFE traded up $0.26 during midday trading on Friday, hitting $29.97. The company’s stock had a trading volume of 30,021,169 shares, compared to its average volume of 30,277,082. The business’s 50 day moving average is $28.40 and its two-hundred day moving average is $27.76. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a market cap of $169.83 billion, a P/E ratio of -499.42, a price-to-earnings-growth ratio of 1.16 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period last year, the company earned $1.23 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.61%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.